Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9815MR)

This product GTTS-WQ9815MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9815MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1107MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ5586MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ3704MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ10614MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ2294MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ7614MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11709MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ12253MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW